Phivida Holdings Inc. (“Phivida” – CSE:VIDA – “US.PHVAF”) is pleased to report that Phivida Organics Inc., a wholly owned US operating subsidiary of Phivida, has entered into a product formulation and wholesale supply agreement with Artelo Biosciences, Inc. (“Artelo”, OTCBB: ARTL).  The purpose of this supply and formulation agreement is to provide pharmaceutical grade cannabidiol (CBD) isolate for research at a prestigious University based in the United Kingdom, sponsored by Artelo.
The Artelo supply agreement names Phivida as a qualified and preferred supplier for cGMP certified active pharmaceutical ingredient (API) grade hemp oil derived CBD isolate for Artelo funded studies. Key terms include mandatory prequalification testing of every batch and lot, verified by a third-party ISO/IEC 17025 certified and cannabinoid testing accredited laboratory using cutting edge High-Performance Liquid Chromatography (HPLC) analysis technology.  Each batch and lot test must produce a Certificate of Analysis (COA) which thoroughly validates product quality (i.e. phytocannabinoids potency and terpenes profile) and safety (i.e. microbiological, residual solvents, pesticides and heavy metal analysis) characteristics.
In addition to pharmaceutical grade isolates, Phivida provides access to a range of premium CBD bulk products derived from certified organic hemp. As a mandatory internal QA/QC standard, Phivida hemp derived products processed at cGMP certified processing facilities using cutting edge super critical Co2 extraction processing technologies.  Beyond isolates, wholesale products include; hot and cold filtered full spectrum CBD Hemp Oil with a rich profile of phytocannabinoids and terpenes (while maintaining <0.3% THC), as well as its flagship nanoencapsulated Hemp Oil extracts and isolates, for enhanced delivery and uptake potential as well as water solubility (used in Phivida branded clinical and consumer beverage products).
“Artelo places a premium on quality, compliance, consistency and reliability.  When we looked for potential suppliers, we were delighted Phivida had already implemented key professional production and testing standards which were critical to Artelo when identifying a partner as an API supplier,” stated Gregory Gorgas, Chief Executive Officer of Artelo.
Phivida President and CEO, John Belfontaine stated; “Phivida is pleased to provide access to API grade CBD for Artelo’s sponsored research initiatives. Phivida management actively supports the scientific research of the safety and efficacy of phytocannabinoids on a wide range of diseases and medical conditions. We value our long term strategic relationships with biopharmaceutical companies like Artelo, and look forward to future opportunities to promote research on cannabinoid pharmacology, participate as a key contributor of API grade CBD, and meaningfully contribute to generating evidence of its potential to improve human health”.  
About Phivida
Phivida [“fiii-vee-daa”] is a publicly traded company listed on the Canadian Securities Exchange under the ticker symbol “VIDA”. Phivida is a premiere brand of cannabidiol (“CBD“) infused functional foods, beverages and clinical health products, poised for global distribution. Using nanoencapsulation technology, Phivida converts lipid based cannabinoids into water soluble delivery format, enhancing bioavailability, and timed released within the body. Phivida’s nanoencapsulated CBD is infused into CBD beverages, foods and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health conditions, from chronic pain to terminal diseases. Phivida Enhanced Inc. (a wholly owned subsidiary of Phivida Holdings Inc.) is the clinical division of Phivida responsible for the formulation, manufacturing and distribution of the professional line clinical products under the brand name Vida+. These clinical grade CBD products include sublingual’s, hard capsules and other full spectrum CBD-hemp oil extract infused nutraceuticals and natural health products. The Vida+ label is a professional line of products clinical grade for higher potency and are third party laboratory tested for cannabinoid potency, terpenes, residual solvents, bacteria and pesticides.  Celebrating; Health and Wellness, In Harmony™, Phivida’s mission is to lead the alternative health care sector as the benchmark quality standard in premium cannabinoid infused foods, beverages and clinical products, with a dedication to research and education while investing back into the communities that we so proudly serve.
SOURCE Phivida Holdings Inc.
For further information: on Phivida visit or: Website; Toll free +1 (844) 744-6646 (ext. #2); Email; Twitter; Facebook; YouTube
Click here to connect with Phivida Holdings Inc (CSE:VIDA) for an Investor Presentation.


MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders – potential industry partners, shareholders and prospective investors – by increasing awareness of its remarkable natural mustard-derived crop protection products.

TODAY: The Future of Food Investment Conference – SnowCap Ventures
Tuesday, Nov. 24th at 1:50 pm ET
Investors Register Here

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of a customer rewards program called “Insider Rewards” for its Urban Juve skin care line.

Cannot view this image? Visit:

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less


  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less